How Do I Decide Which Grant Is Appropriate?

Potential applicants should prepare a letter of interest that briefly identifies the proposed research and includes a plan for the development of CIPRA activities/capabilities.

More information about how to prepare the letter of interest is available at the CIPRA Web site:

http://www.niaid.nih.gov/daids/cipra

Upon receipt of the letter, NIAID staff will contact the applicant to discuss the proposed plan. NIAID staff will recommend which type of grant (A, B, or C) would be most appropriate and will also provide appropriate guidance for preparing the grant application.

There is no deadline for the letter of interest; it may be submitted at any time.

For More Information about CIPRA

Information about CIPRA can be found on the Web at:

http://www.niaid.nih.gov/daids/cipra

Contact CIPRA staff by e-mail at: cipra@niaid.nih.gov

Or write to:
Dr. Rodney Hoff
Division of AIDS
National Institute of Allergy and
Infectious Diseases
National Institutes of Health
Room 4157, MSC-7628
Bethesda, MD 20892-7628
U.S.A.

For courier or express delivery: Use zip code 20817



Division of AIDS National Institute of Allergy and Infectious Diseases National Institutes of Health

Comprehensive International Program of Research on AIDS





National Institute of Allergy and Infectious Diseases
National Institutes of Health

What Is CIPRA?

CIPRA is a program that supports comprehensive research and development efforts at organizations located in eligible nations to develop practical, affordable, and acceptable methods to prevent and treat HIV/AIDS in adults and children. The goals of CIPRA are to:

- 1. Provide long-term support for planning and implementing a comprehensive HIV/AIDS research agenda, including epidemiological, clinical, and laboratory research. Such research should form the basis for the development and application of practical and affordable methods to prevent and treat HIV/AIDS in the host country or countries.
- 2. Enhance the capability and capacity of the applicant organization to conduct research that is relevant to the affected population(s). Provide support for continual training of project staff at all levels so that the organization can develop and maintain skilled staff. Provide support for infrastructure development (facilities, renovations, and equipment) and for developing the organizational capability necessary to build and sustain an ongoing research effort.

What Will CIPRA Support?

Three different levels of CIPRA support will be available depending on the capability of the applicant organization to conduct research:

- A. CIPRA Planning and Organizational (R03) Grants will provide 1 or 2 years of support, up to \$50,000 (direct costs) per year for institutions in nations with very limited HIV/AIDS research experience and capacity, or to institutions that need support while preparing an application for one of the larger CIPRA grants (below).
- **B. CIPRA Exploratory/Developmental Research (U01) Grants** will provide
 up to 5 years of support at a maximum
 total cost of \$500,000 per year to
 develop a comprehensive HIV/AIDS
 research program.
- C. CIPRA Multi-Project Research
 (P01 or U19) Grants will provide up to
 5 years of support (potentially renewable)
 to conduct multiple, coordinated research
 projects focused on developing or implementing preventive and therapeutic
 interventions for HIV/AIDS and associated
 opportunistic infections, and tuberculosis
 in the host country or countries.

Who Can Apply for a CIPRA Grant?

Applications must come from research or clinical care organizations located in eligible countries. Eligibility requires a per capita annual gross national product (GNP) equal to or less than U.S. \$5,000, as listed at: http://www.worldbank.org/aids-econ/confront/appendix/apdxtbl2a.htm

Please note that this table is a classification of countries with selected economic data and includes countries that are eligible for CIPRA funds, as well as those that are not eligible.

The research must be led by host country investigators and conducted primarily in the host country. Collaboration with investigators from the United States and other international organizations is encouraged but not required. U.S. institutions are not eligible to apply.